" "@en . . . "approved"@en . "Rimexolone"@en . . . . . . . . . . . . . . "Humans and other mammals"@en . . . . . . . . . . "Symptoms of overdose include retinal toxicity, glaucoma, and subcapsular cataract."@en . . . . . . . "Following IV administration of radio-labelled rimexolone to rats, greater than 80% of the dose is excreted via the feces as rimexolone and metabolites."@en . . . . . . . . "Rimexolone is a glucocorticoid receptor agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. By binding to the glucocorticoid receptor, this drug ultimately leads to changes in genetic transcription involving the lipocortins and prostaglandins."@en . "49697-38-3"@en . . . . . . . "Rimexolone is a glucocorticoid steroid used to treat inflammation in the eye. It is marketed as a 1% eye drop solution under the trade name Vexol"@en . . . . . . . "Systemically absorbed."@en . . "The serum half-life of rimexolone could not be reliably estimated due to the large number of samples below the quantitation limit of the assay (80 pg/mL). However, based on the time required to reach steady-state, the half-life appears to be short (1-2 hours)."@en . "For the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis."@en .